Zomedica Corp. (NYSE American: ZOM) today announced that Larry Heaton, CEO, will be attending the Q3 Virtual Investor Summit. During the presentation, Zomedica Chief Executive Officer, Larry Heaton, will highlight the Company's recent acquisitions and integration of PulseVet and the assets of Revo Squared and Assisi Animal Health, and the resulting transformational business strategy, noteworthy collaborations and partnerships, and the broader going-forward corporate vision. The presentation will be webcast and an archived recording will be made available in the Investors' section of the Zomedica website.
Event: | Q3 Investor Summit |
Date: | August 16 & 17th, 2022 |
Presentation: | August 16 @ 12:30 p.m. ET |
Location: | https://us06web.zoom.us/webinar/register/WN_FfufrTaxTkSpRc1P4NPAAA |
Company Description
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. Zomedica's TRUFORMA® is an in-clinic biosensor platform offering reference lab quality results for diagnoses of thyroid and adrenal disorders. The PulseVet® line is the leader in veterinary shock wave therapy, and has recently launched technology capable of delivering true electrohydraulic shock wave energy without the need for sedation.
Investor Relations Contact:
PCG Advisory Group
Kirin Smith, President
This email address is being protected from spambots. You need JavaScript enabled to view it.
+1.646.823.8656
About Investor Summit Group
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors. The Q3 Investor Summit will take place virtually, featuring 90+ companies and over 500 investors comprising institutional investors, family offices, and high net worth investors. Sectors Participating: Biotech, Communication Services, Consumer, Energy, Energy/Tech, Financial, Healthcare, Industrials, Materials, Real Estate, Technology, and Tech/Crypt. Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$0.05 |
Daily Volume: | 587,432 |
February 06, 2025 December 23, 2024 November 27, 2024 November 14, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREC4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREEnd of content
No more pages to load